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Abstract The obstructive sleep apnea syndrome (OSAS) is
associated with cardiovascular abnormalities including left
ventricular hypertrophy, left ventricular diastolic dysfunc-
tion, and endothelial dysfunction. The present study
evaluated whether N-terminal pro-B-type natriuretic peptide
(NT-proBNP) and peak oxygen consumption (peak VO2),
both integral markers of cardiovascular function, are related
to OSAS severity. In addition, we tested whether NT-
proBNP levels depend on body composition in OSAS
patients, similar to what has been reported in patients
without OSAS. Eighty-nine patients with untreated OSAS
underwent NT-proBNP measurement, dual X-ray absorpti-
ometry, and cardiopulmonary exercise testing. In a repre-
sentative subgroup (n=32), transthoracic echocardiography
was performed. The severity of OSAS was classified based
on apnea–hypopnea index (AHI) values as mild (AHI
5–15 h−1), moderate (AHI 15–30 h−1), and severe
(AHI >30 h−1). OSAS was mild in 19 (21%), moderate in
21 (24%), and severe in 49 (55%) patients. NT-proBNP
levels did not differ among patients with mild [30 (10–57)],
moderate [37 (14–55)], and severe [24 (13–49) pg/ml; p=
0.8] OSAS and were not related to body mass index (r=
0.07; p=0.5), percent lean body mass (r=−0.17; p=0.1),
and percent fat mass (r=0.18; p=0.1). Percent predicted
peak VO2 was on average normal and did not differ among
patients with mild (115±26), moderate (112±23), and
severe OSAS (106±29%; p=0.4). Body weight-indexed
peak VO2 did not differ among patients with mild (31.9±
10.3), moderate (32.1±7.9), and severe OSAS (30.0±
9.9 ml kg−1 min−1; p=0.6) either. Lower NT-proBNP
(β=−0.2; p=0.02) was independently but weakly associated
with higher body weight-indexed peak VO2. In the
echocardiography subgroup, NT-proBNP was not signifi-
cantly related to left ventricular mass index (r=0.26; p=
0.2). In conclusion, NT-proBNP and peak VO2 are not
related to OSAS severity, and NT-proBNP poorly reflects
left ventricular hypertrophy in OSAS. The lack of a
relationship between NT-proBNP and OSAS severity is
not due to a significant influence of body composition on
NT-proBNP. There is an association between higher NT-
proBNP and lower peak VO2, indicating that NT-proBNP is
a marker of cardiorespiratory fitness in patients with OSAS.
However, the association is too weak to be clinically useful.
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Introduction
The obstructive sleep apnea syndrome (OSAS) is associated
with various cardiovascular abnormalities, including in-
creased sympathetic nerve activity [1], subclinical athero-
sclerosis [2], endothelial dysfunction [3], left ventricular
hypertrophy [4, 5], and left ventricular diastolic dysfunction
[4, 6, 7]. There is an association between OSAS and
hypertension [8], and OSAS has also been recognized as a
risk factor for the development and progression of heart
failure [9]. These cardiovascular abnormalities appear to
depend on the severity of OSAS [5, 7, 8, 10], and many of
them are attenuated or reversed after treatment with
continuous positive airway pressure ventilation [2, 3, 6, 11].
B-type natriuretic peptide (BNP) and the N-terminal
fragment of its precursor peptide (N-terminal pro-B-type
natriuretic peptide; NT-proBNP) aremarkers of cardiomyocyte
stretch and, thereby, cardiac dysfunction. There is an associ-
ation between BNP and/or NT-proBNP and left ventricular
hypertrophy [12, 13], left ventricular diastolic dysfunction
[14, 15], and impaired functional capacity [16–18]. Thus,
BNP and NT-proBNP might be suitable biomarkers to detect
subclinical cardiovascular stress induced by OSAS, and given
the relationship between OSAS severity and cardiac dysfunc-
tion [5, 7, 10], BNP and NT-proBNP might be related to the
presence and severity of OSAS. However, previous studies
failed to identify such an association [19–22]. All these
studies, however, were either comparatively small or had
other limitations, including a long time interval between sleep
study and hormone measurement [19] and the use of BNP
instead of NT-proBNP [19, 20], the former having a much
shorter half-life (20 min) than NT-proBNP (several hours)
[23, 24]. Furthermore, apart from testing the association
between BNP/NT-proBNP and the presence and severity of
OSAS, no attempts have been made to establish the
relationship between circulating BNP or NT-proBNP levels
and cardiovascular abnormalities in OSAS. In particular, it is
unknown whether BNP and NT-proBNP levels are related to
exercise capacity, similar to what had been reported in
subjects with heart failure [17, 18]. In patients not limited by
pulmonary disease or musculoskeletal problems, exercise
capacity is an integral measure of cardiovascular perfor-
mance. Interestingly, data on exercise testing in patients with
OSAS but without overt cardiovascular disease are quite
sparse [25–27].
Assuming more severe cardiovascular dysfunction and
thus increased myocyte stretch at rest and impaired cardiac
output during exercise in patients with more severe OSAS,
we hypothesized that NT-proBNP levels and peak oxygen
consumption (peak VO2) depend on disease severity
expressed as the apnea–hypopnea index (AHI) in a native
OSAS population without obvious cardiac disease. Further-
more, we hypothesized that NT-proBNP and peak VO2
would also be related in OSAS patients. Finally, as a
previous study revealed a relationship between NT-proBNP
and body mass index and body composition [28], we
evaluated whether this also applies for OSAS patients and
thereby might influence the relationship between NT-
proBNP levels, measures of OSAS severity, and cardiovas-
cular performance.
Materials and methods
Patients and protocol
We studied 96 outpatients with a new diagnosis of OSAS
established by polysomnography. Only patients with a
normal electrocardiogram (sinus rhythm, absence of signif-
icant Q waves, or left-bundle-branch-block) were eligible.
Patients with a history of heart failure, significant pulmo-
nary disease, anemia, peripheral arterial occlusive disease,
or other conditions limiting exercise capacity were excluded.
All patients underwent measurement of NT-proBNP and
serum creatinine, cardiopulmonary exercise testing with gas
exchange techniques, and dual X-ray absorptiometry. Due to
the relationship between NT-proBNP and renal function [29],
patients with an estimated glomerular filtration rate [30]
<30 ml/min/1.73 m2 were not included in the analysis. In the
last 32 consecutive patients included in the study, an
echocardiogram was also performed to verify that only
patients with preserved left ventricular systolic function were
studied as attempted by the inclusion criteria and to test the
association between NT-proBNP and left ventricular hyper-
trophy and measures of left ventricular diastolic dysfunction.
All examinations were performed within 1 to 3 days before
institution of continuous positive airway pressure ventilation.
The study was performed in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki.
Participants gave written informed consent, and the local
ethics committee approved the study protocol.
Polysomnography
Fully supervised polysomnography was performed in all
patients using a commercially available monitoring system
(Mepal, MAP Medizin-Technologie, Martinsried, Germany).
Minimum time spent in the laboratory was 6 h. Sleep was
measured with the three standard electroencephalographic
channels. Electromyographic signals were collected for eye
movements, chin activity, and leg movements. Respiration
was traced with thoracic and abdominal piezoelectric bands,
and air flow was measured with nasal pressure prongs. All
studies were analyzed by an experienced sleep technologist
supervised by a physician specialized in sleep medicine.
Apnea was defined as complete (>80%) reduction in the
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flow signal (assessed via nasal pressure prongs) lasting for
≥10 s, and hypopnea was defined as >50% reduction in the
airflow signal lasting for ≥10 s accompanied by a decrease in
oxygen saturation >3% or an arousal. The AHI was defined
as the number of episodes of apnea and hypopnea per hour
of sleep monitored. The diagnosis of OSAS was based on
symptoms of daytime sleepiness (according to the Epworth
sleepiness scale [31]) and an AHI ≥5 h−1 [32]. The severity
of OSAS was classified based on AHI values as mild (AHI
5–15 h−1), moderate (AHI 16–30 h−1), and severe
(AHI >30 h−1). As additional measures of the severity of
OSAS, arousal index and desaturation index were assessed.
Assessment of body composition
Weight was measured to the nearest 0.1 kg on a calibrated
scale, and height was determined using a wall-mounted
stadiometer. Body mass index was calculated as weight (in
kg) divided by height to the power of two, and body surface
area was calculated using the Mosteller formula [33]. Lean
body mass was determined by dual X-ray absorptiometry
[34] using a commercially available scanner (Lunar DPX-NT,
Lunar, General Electrics Healthcare, Munich, Germany). We
used the scanner-installed software package (Encore Version
6.7). The subjects were measured in light clothing. The
scanner was calibrated every morning, and three times a week,
a bone phantom scan was used to determine scan quality.
Laboratory analysis
After an overnight fast, serum samples were collected at
7:00 A.M. into EDTA tubes and stored at −70°C for later
analysis. NT-proBNP was measured in 2006 using a
commercially available highly sensitive and specific im-
munoassay based on double antibody sandwich technique
(Elecsys proBNP, Roche Diagnostics, Basel, Switzerland)
[35, 36]. The technicians involved in NT-proBNP analysis
were blinded to clinical data.
Cardiopulmonary exercise testing
Participants underwent cardiopulmonary exercise testing on
a treadmill ergometer (CS-200, Schiller, Baar, Switzerland).
All tests were performed between 3:00 and 7:00 P.M. under
regular medication. Before the test, the tightness of the
facemask was adjusted manually to avoid leakage. To allow
familiarization with the test mode, the protocol started with
a warm-up period of 6 min of constant work load (speed
1.6 km/h, inclination 6%), followed by an individualized
ramp protocol, which was selected according to the
patient’s subjective estimate of physical fitness from a set
of 12 ramp protocols for exercise capacities ranging from 4
to 17 metabolic equivalents (as estimated from speed and
grade of the treadmill) to achieve a test duration of
approximately 10 min (ramp portion of the test) [37].
During the tests, subjects were verbally encouraged to
exercise until exhaustion. A 12-lead electrocardiogram was
recorded continuously, and blood pressure (by indirect arm-
cuff sphygmomanometry) was assessed every 2 min.
Expired gases were acquired continuously, and oxygen
consumption and carbon dioxide output (VCO2) were
recorded in rolling 30-s averages (ErgoScope, Ganshorn,
Niederlauer, Germany). Calibration of the system was
performed before each test.
Functional capacity was expressed as peak VO2 (abso-
lute, percent predicted from age, gender, and height [38],
and indexed to body weight). For each test, the relation
between minute ventilation (VE) and VCO2 was plotted to
determine the VE/VCO2 slope. All data points from the
beginning to the end of exercise were included to determine
the VE/VCO2 slope [39]. To ensure appropriate effort, only
subjects achieving a respiratory exchange ratio (i.e., VCO2
divided by oxygen consumption) ≥1.0 at peak exercise
were included in the analysis.
Echocardiography
Echocardiographic studies (Toshiba Powervision 8000,
Osaka, Japan) were performed by one single operator using
standard techniques [40]. Measures of left ventricular and
left atrial dimensions were obtained in the parasternal long
axis view. Left ventricular mass was calculated based on an
anatomically validated formula [41]. All measurements
were indexed to body surface area. Left ventricular
hypertrophy was defined as a left ventricular muscle mass
index (LVMI) >125 g/m2 in men and >110 g/m2 in women,
which is the definition employed in a previous study
showing a relationship between BNP and left ventricular
mass index in patients with hypertension [13] to allow
comparison with that study. Left ventricular ejection
fraction (LVEF) was determined from the apical view by
biplane calculation or visual estimation in case of a poor
acoustic window. The pulse-wave Doppler sample was
placed at the tips of mitral valve leaflets in the apical four-
chamber view, and the ratio of the peak flow velocity in
early diastole and the peak flow velocity at atrial contrac-
tion (E/A ratio) and deceleration time were determined.
Statistical analysis
Statistical analysis was performed using a commercially
available software package (SPSS, Version 10.1, Chicago,
IL, USA). Categorical data were expressed as numbers and
percentages. Continuous data were expressed as the mean±
SD or the median (interquartile range) where appropriate.
The chi-square test was used to compare categorical data.
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For comparison of continuous data, the unpaired t test or
the Mann–Whitney U test was used as appropriate. For
comparison of several groups, the chi-square test, analysis
of variance (ANOVA), or the Kruskal–Wallis test was
applied. Pearson’s or Spearman’s rank correlation coeffi-
cients were calculated to identify associations between
parameters of interest.
Multiple linear regression analysis was performed to
identify pretest predictors of peak VO2. For variables with a
skewed distribution, ln-transformed values were employed.
Variables with a p value <0.1 at the univariate analysis were
included in the multivariate model (forward stepwise
technique). A receiver operator characteristics (ROC) curve
was constructed for the ability of NT-proBNP to predict a
peak VO2 <20 ml kg
−1 min−1, a widely used cut-off for an
impaired exercise capacity [42], and the area under the
ROC curve was determined. A p value <0.05 was
considered statistically significant.
Results
Patients
Of 96 patients undergoing cardiopulmonary exercise
testing, seven were excluded because of a respiratory
exchange ratio <1.0, leaving 89 patients for the present
analysis. Patient characteristics are shown in Table 1.
OSAS was mild in 19 (21%), moderate in 21 (24%), and
severe in 49 (55%) patients. Patients with severe OSAS
were more likely to be male and had higher absolute lean
body mass than those with mild and moderate OSAS. Body
Table 1 Patient characteristics
All AHI 5–15 h−1 AHI 15–30 h−1 AHI >30 h−1 p value
Number 89 19 21 49
Age (years) 49.5±9.7 48.4±9.1 47.6±8.4 50.1±10.5 0.4
Gender (female) 11 (12%) 6 (32%)** 4 (19%)*** 2 (4%)**, *** 0.002
Body composition
Height (cm) 173±8 171±8 173±7 175±8 0.1
Weight (kg) 91±14 85±12** 87±10 94±15** 0.02
Body mass index (kg/m2) 30.2±4.6 29.4±5.1 29.3±4.1 30.9±4.5 0.3
Lean body mass (kg) 55.6 (51.6–60.6) 53.0 (47.0–55.2)** 53.7 (50.7–58.9)*** 58.5 (54.7–63.1)**, *** <0.001
Lean body mass (%) 65 (59–68) 64 (56–68) 65 (58–68) 64 (60–68) 0.8
Fat mass (kg) 27.9 (23.5–35.6) 25.7 (23.1–33.3) 25.9 (22.7–34.0) 29.1 (24.3–36.2) 0.6
Fat mass (%) 33 (29–39) 33 (29–41) 32 (30–40) 34 (29–39) 0.8
Cardiovascular risk factors
Hypertension 56 (63%) 11 (58%) 8 (38%)*** 37 (76%)*** 0.01
Hypercholesterolemia 73 (82%) 13 (68%) 18 (86%) 42 (86%) 0.2
Diabetes 9 (10%) 1 (5%) 1 (5%) 7 (14%) 0.4
Smoking 52 (58%) 10 (53%) 12 (57%) 30 (61%) 0.9
Medication
ACEI or ARB 19 (21%) 2 (11%) 2 (10%) 15 (31%) 0.06
β-blockers 11 (12%) 3 (16%) 2 (10%) 6 (12%) 0.8
Diuretics 15 (17%) 2 (11%) 2 (10%) 11 (22%) 0.3
Calcium channel blockers 9 (10%) 0 2 (10%) 7 (14%) 0.2
Aspirin 8 (9%) 1 (5%) 1 (5%) 6 (12%) 0.5
Statin 15 (17%) 1 (5%) 2 (10%) 11 (22%) 0.2
OSAS severity
Epworth sleepiness score 13 (9–15) 14 (9–17) 13 (10–15) 11 (9–15) 0.4
AHI (h−1) 34 (17–53) 11 (8–12)*, ** 25 (18–27)*, *** 52 (38–74)**, *** <0.001
Arousal index (h−1) 44 (28–63) 23 (17–35)** 34 (28–41)*** 60 (46–80)**, *** <0.001
Desaturation index (h−1) 15 (7–37) 5 (3–7)*, ** 10 (6–15)*, *** 36 (21–48)**, *** <0.001
GFR (ml/min/1.73 m2) 92.9±14.1 92.0±8.6 96.3±15.5 91.7±15.2 0.5
The p values are given for the results of ANOVA, chi-square, or Kruskal–Wallis test, respectively.
AHI Apnea–hypopnea index, ACEI angiotensin-converting-enzyme inhibitors, ARB angiotensin-receptor blockers, OSAS obstructive sleep apnea
syndrome, GFR glomerular filtration rate
*p<0.05 for AHI 5–15 vs AHI 15–30 h−1 (results of post hoc testing)
**p<0.05 for AHI 5–15 vs AHI >30 h−1 (results of post hoc testing)
***p<0.05 for AHI 15–30 vs AHI >30 h−1 (results of post hoc testing)
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weight was higher in patients with severe than those with
mild OSAS. Patients with severe OSAS were more likely to
have hypertension as compared to patients with moderate
OSAS. As expected, the groups differed with respect to
objective measures of OSAS severity. However, they were
similar with respect to the Epworth sleepiness scale and
other characteristics.
NT-proBNP and OSAS severity
The median NT-proBNP value was 24 (13–49) pg/ml. NT-
proBNP values did not differ across different AHI
categories (p=0.8) as shown in Fig. 1. There was no
significant relationship between NT-proBNP and Epworth
sleepiness score (r=0.17; p=0.1), arousal index (r=0.03;
p=0.7), or desaturation index (r=−0.05; p=0.7).
As there were significant gender differences across the
AHI categories, analysis was repeated after exclusion of the
11 female subjects. However, NT-proBNP values did not
differ among men with mild [18 (8–38) pg/ml], moderate
[23 (14–52) pg/ml], and severe [24 (13–49) pg/ml] OSAS
(p=0.57).
NT-proBNP and body composition
NT-proBNP was not related to body mass index (r=0.07;
p=0.5) nor absolute (r=−0.13; p=0.2) or percent lean body
mass (r=−0.17; p=0.1) nor total (r=0.14; p=0.2) or
percent fat mass (r=0.18; p=0.1).
Functional capacity and OSAS severity
Data from cardiopulmonary exercise testing are shown in
Table 2. No patients showed an ischemic response. Patients
with mild OSAS had higher diastolic blood pressure at rest
as compared to patients with moderate OSAS, and patients
with moderate OSAS had lower systolic blood pressure at
peak exercise as compared to the other two AHI groups.
However, peak heart rate, absolute peak VO2, percent
predicted peak VO2, and peak VO2 indexed for body
weight did not differ across the AHI categories. Among the
whole study population, 11 (12%) patients had a peak
VO2 <20 ml kg
−1 min−1. Values for the VE/VCO2 slope
were generally very low and did not differ across the AHI
categories.
If the 11 female subjects were excluded from the
analysis, absolute (p=0.41) and percent predicted (p=
0.31) peak VO2 did not differ among men with mild,
moderate, and severe OSAS either. Percent predicted peak
VO2 was on average normal in men with mild (116±26%),
moderate (111±19%), and severe (105±28%) OSAS.
ANOVA revealed lower body weight-indexed peak VO2
in men with more severe OSAS (p=0.02), but body mass
index was higher in more severe OSAS (p=0.02). Further
analysis by post hoc testing (Bonferroni) revealed only
borderline differences with respect to body weight-indexed
peak VO2 (p=0.055) and body mass index (p=0.062) in
subjects with AHI between 5 and 15 h−1 and those with
AHI >30 h−1. Otherwise, no differences were obtained.
Exercise capacity and NT-proBNP
There was a moderate correlation between ln NT-proBNP
and peak VO2 (Fig. 2). In the univariate analysis, peak VO2
was also associated with age (r=−0.42; p<0.001), gender
(r=−0.32; p=0.02), body mass index (r=−0.50; p<0.001),
resting heart rate (r=−0.30; p=0.004), ln arousal index (r=
0.25; p=0.02), and ln desaturation index (r=−0.23; p=
0.03). There was no significant association between peak
VO2 and ln AHI (r=−0.15; p=0.17). In the multivariate
model, male gender (β=0.23; p=0.008), younger age
(β=−0.29; p=0.001), lower body mass index (β=−0.35;
p<0.001), lower resting heart rate (β=−0.24; p=0.004),
and lower NT-proBNP (β=−0.2; p=0.02) were indepen-
dently associated with higher peak VO2. However, the area
under the ROC curve for the ability of NT-proBNP to
predict a peak VO2 <20 ml kg
−1 min−1 was only 0.55 (p=
0.6). An optimal NT-proBNP cut-off of 24 pg/ml had
sensitivity of 73% and a specificity of 50% for the
prediction of a peak VO2 <20 ml kg
−1 min−1.
Left ventricular mass and function
Patients undergoing echocardiography (n=32) and patients not
doing so (n=57) were similar with respect to age (49.1±8.4
vs 49.8±10.5 years; p=0.7), body mass index (29.4±5.7 vs
30.6±3.8 kg/m2; p=0.2), AHI [32 (16–57) vs 37 (24–52) h−1;
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Fig. 1 Boxplots showing NT-proBNP values in different AHI
categories. Boxes indicate median values and interquartile ranges
Sleep Breath (2008) 12:7–16 11
p=0.5], and NT-proBNP [25 (14–48) vs 22 (11–61); p=0.70];
thus, the echocardiography subgroup was representative of the
entire study population.
Echocardiography findings are presented in Table 3.
Four (13%) patients had left ventricular hypertrophy. All
patients had an LVEF ≥50%. There was a significant
correlation between AHI and left ventricular posterior wall
thickness. Otherwise, AHI was not related to any echocar-
diographic parameter. NT-proBNP was not significantly
related to LVMI. If left ventricular mass was indexed as
height to the power of 2.7 instead of body surface, NT-
proBNP was similarly not related to LVMI. There was a
trend toward a correlation between NT-proBNP and LVEF
(p=0.06).
Discussion
The present study confirms previous findings in that, in
OSAS patients, NT-proBNP levels were generally low and
not related to disease severity as expressed by AHI. In
addition, our findings suggest that this is not due to a
significant influence of body composition on NT-proBNP
levels. There was a statistically significant but compara-
tively weak independent relationship between NT-proBNP
and functional capacity.
In previous studies, BNP or NT-proBNP levels measured
before [20, 22, 43] or after [20–22, 44] sleep were not
found to be elevated in patients with OSAS. Similarly, a
recent analysis among 623 patients from the Framingham
study did not find an association between AHI and BNP
[19]. However, in the latter study, the median time between
BNP measurement and polysomnography of 79 (27–280)
days is an important limitation given that the half-life of
BNP is approximately 20 min [23]. In the present
examination, which to the best of our knowledge is the
largest and most detailed study on NT-proBNP in OSAS,
patients underwent phlebotomy in the morning after
polysomnography, and the more stable NT-proBNP (half-
life several hours) [24] instead of BNP was measured.
Despite this, there was nevertheless no association between
subjective measures of daytime sleepiness and objective
measures of OSAS severity.
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Fig. 2 Scatter plot showing the relationship between NT-proBNP (ln-
transformed values) and peak VO2
Table 2 Cardiopulmonary exercise testing results
All AHI 5–15 h−1 AHI 15–
30 h−1
AHI >30 h−1 p values
Number 89 19 21 49
Exercise time (s) 517 (463–597) 517 (459–573) 481 (447–598) 527 (467–614) 0.7
Heart rate at rest (bpm) 86±14 81±12 89±15 87±14 0.2
Peak heart rate (bpm) 160±18 161±18 164±16 157±19 0.3
Systolic BP at rest (mmHg) 136±19 139±23 130±15 138±18 0.2
Peak systolic BP (mmHg) 199±28 204±31* 183±23*, ** 203±26** 0.01
Diastolic BP at rest (mmHg) 89±10 92±11* 84±9* 89±10 0.03
Peak diastolic BP (mmHg) 91±15 92±16 88±10 92±16 0.6
RER at peak exercise 1.15±0.08 1.15±0.09 1.16±0.09 1.14±0.08 0.7
Peak VO2 (l/min) 2.76±0.80 2.69±0.83 2.76±0.70 2.78±0.85 0.9
Percent predicted peak VO2 110±27 115±26 112±23 106±29 0.4
Peak VO2 BW (ml kg
−1 min−1) 30.9±9.5 31.9±10.3 32.1±7.9 30.0±9.9 0.6
VE/VCO2 slope 23.5±2.8 24.0±2.5 23.6±3.5 23.2±2.5 0.6
The p values are given for the results of ANOVA and the Kruskal–Wallis test, respectively.
AHI Apnea–hypopnea index, BP blood pressure, peak VO2 peak oxygen consumption, peak VO2 BW peak VO2 indexed for body weight, RER
respiratory exchange ratio, VE/VCO2 slope relationship between minute ventilation and carbon dioxide production
*p<0.05 for AHI 5–15 vs AHI 15–30 h−1 (results of post hoc tests)
**p<0.05 for AHI 5–15 vs AHI >30 h−1 (results of post hoc tests)
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In the Framingham population, the authors concluded
that OSAS in their cross-sectional setting was not associ-
ated with persistent daytime left ventricular dysfunction as
reflected in morning natriuretic peptide levels [19]. Al-
though this is a possible explanation for the negative
findings, one should also consider the alternative possibility
that left ventricular dysfunction and other cardiovascular
abnormalities were present, but were not reflected by BNP.
Natriuretic peptide levels are influenced by many factors
other than left ventricular wall stress, and it has not been
determined whether BNP and NT-proBNP levels in OSAS
patients actually reflect left ventricular wall stress and its
echocardiographic surrogates. In patients with hyperten-
sion, an association between BNP and LVMI (left ventric-
ular mass indexed to body weight) has been reported [13].
However, in the present study, the relationship between NT-
proBNP and LVMI did not reach statistical significance,
even when left ventricular mass was indexed to height to
the power of 2.7 as suggested for obese subjects [45], nor
was NT-proBNP related to measures of left ventricular
diastolic dysfunction. The only association between NT-
proBNP and echocardiographic measures was a trend
toward a correlation with LVEF, although LVEF was
preserved in all patients. Thus, NT-proBNP clearly did not
accurately reflect left ventricular hypertrophy and dysfunc-
tion in our study subgroup, which was representative for the
whole sample with respect to age, body mass index, AHI,
and NT-proBNP.
There is evidence for a relationship between OSAS and
congestive heart failure [9], and impaired exercise tolerance
is a hallmark of this condition [16]. Peak VO2 is closely
related to cardiac output [46], which in turn depends on
preload, left ventricular systolic and diastolic function, and
afterload, the latter two factors being abnormal in many
OSAS patients according to previous studies [3, 4, 6, 8].
Interestingly, data on exercise capacity in OSAS patients
are sparse and conflicting [25–27]. Whereas in the study by
Oztürk et al. [25], peak VO2 values were similar in OSAS
patients and controls; Lin et al. [26] reported lower peak
VO2 in patients with OSAS as compared to controls. In a
retrospective analysis, Guillermo et al. [27] found lower
peak VO2 in patients with AHI >20 h
−1 as compared to
controls, whereas overall peak VO2 did not differ among
patients with OSAS and controls. In the present study
among OSAS patients without obvious cardiac disease,
peak VO2 was overall normal without significant differ-
ences across the AHI categories. This indicates that OSAS
per se—even if severe—is not necessarily associated with
impaired exercise tolerance, and that any cardiovascular
abnormalities—if present—must be regarded as subclinical.
However, many patients had antihypertensive therapy, and
blood pressure values were normal or only moderately
elevated in most cases. Results might have been different if
blood pressure would have been untreated. Values for the
VE/VCO2 slope were normal across the AHI groups, which
well fits the fact that exercise capacity was normal.
Although untreated severe OSAS is associated with a
higher risk of fatal and nonfatal cardiovascular events when
compared to healthy people and patients with wild or
moderate OSAS [47], and NT-proBNP is a predictor of
major cardiovascular events and death [48], peak VO2 and
NT-proBNP values did not differ among the AHI sub-
groups, which is an unexpected finding.
In patients with heart failure, peak VO2 has been found
to be moderately related to BNP and NT-proBNP [17, 18],
and it has even been proposed that BNP might be used to
Table 3 Left ventricular structure and function and relationship with AHI and NT-proBNP (n=32)
Echo parameter Echo vs AHI Echo vs NT-proBNP
R p R p
Left ventricular end-diastolic diameter (mm/m2) 23.1±2.9 −0.15 0.4 0.005 1.0
Left ventricular end-systolic diameter (mm/m2) 15.3±2.8 −0.08 0.6 −0.05 0.8
Interventricular septal diameter (mm/m2) 5.8±0.9 −0.2 0.2 0.05 0.8
Left ventricular posterior wall diameter (mm/m2) 4.8±0.8 −0.47 0.007 0.25 0.2
Relative wall thickness 0.42±0.09 −0.26 0.2 0.18 0.3
Left ventricular mass (g) 173 (151–220) 0.002 1.0 0.18 0.3
Left ventricular mass index (g/m2) 85 (77–101) −0.12 0.6 0.26 0.2
Left ventricular mass index (g/m2.7) 42.1 (33.1–50.7) −0.09 0.6 0.17 0.3
Left ventricular ejection fraction (%) 63±5 −0.19 0.3 0.34 0.06
Left atrial size (mm/m2) 17.9±2.3 −0.12 0.5 0.14 0.4
Peak flow velocity in early diastole (E; m/s) 0.66 (0.57–0.76) −0.3 0.1 0.05 0.8
Peak flow velocity at atrial contraction (A; m/s) 0.66 (0.54–0.78) 0.06 0.8 0.25 0.2
E/A ratio 0.91 (0.80–1.28) −0.2 0.3 −0.17 0.4
Deceleration time (ms) 222 (193–259) 0.24 0.2 0.12 0.5
R Spearman’s correlation coefficients between echocardiographic measures and AHI and NT-proBNP, respectively
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predict low exercise capacity in these patients [17].
Interestingly, NT-proBNP was also associated with peak
VO2 in the present study of OSAS patients without
symptoms and signs of heart failure. However, similar to
the relationship between peak VO2 and BNP in patients
with mild-to-moderate chronic heart failure undergoing
treadmill exercise (r=−0.31; p<0.05) [18], this correlation
was only moderate (r=0.33), and although interesting from
a pathophysiological point of view, it might not be
clinically useful.
Several recent studies revealed an inverse relationship
between natriuretic peptides and body mass index [28, 49,
50], suggesting that cut-points for natriuretic peptides for
the diagnosis of acute heart failure [51] and the prediction
of prognosis in chronic heart failure [52] should be adjusted
for body mass index. We, therefore, considered that low
NT-proBNP levels in OSAS patients might be due to
frequent coexisting obesity and altered body composition.
However, in contrast to a previous publication [28], we did
not find an association between NT-proBNP and body mass
index and body composition, and thus, lack of a relation-
ship between OSAS severity NT-proBNP levels is not due
to a significant influence of body composition on NT-proBNP.
Limitations
Our study has several limitations. The sample size was
small, and there was no control group of similarly obese
patients without OSAS. A second limitation was the lack of
a more systematic and detailed examination of left
ventricular diastolic function. The E/A ratio and decelera-
tion time are imperfect measures of left ventricular diastolic
function due to their U-shaped relationship with the severity
of left ventricular diastolic dysfunction. However, it has been
previously observed that most OSAS patients without
significant associated cardiac disease have a normal mitral
filling pattern or impaired relaxation, and that more advanced
left ventricular diastolic dysfunction (i.e., pseudonormal and
restrictive patterns) is rare [6]. Given the inclusion criteria,
mean deceleration time and atrial size values, this was also
likely the case in our population. Accordingly, a lower E/A
ratio and a longer deceleration time might have been
acceptable although imperfect parameters for more impaired
relaxation.
Conclusions
Circulating levels of NT-proBNP do not reflect OSAS
severity as expressed by AHI, and this is not due to a
significant influence of body composition on NT-proBNP
levels. However, this does not necessarily mean that left
ventricular hypertrophy and dysfunction are absent, as
indicated by the poor correlation between NT-proBNP and
measures of left ventricular hypertrophy and diastolic
dysfunction. A new observation is that that a higher NT-
proBNP level is an independent predictor of a lower peak
VO2, indicating that NT-proBNP is global marker of
cardiopulmonary fitness. However, the association is too
weak to be clinically useful.
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